

NEW LIFE FOR PATIENTS SUFFERING FROM BLEPHARITIS

Milan, June 5, 2019 – Recently, a controlled clinical study was presented on Blefastop, an ocular and periocular innovative therapeutic solution as adjuvant in blepharitis.

Many treatments today are unfortunately not ideal as an effective daily treatment of blepharitis, and as a result, blepharitis is still an unresolved problem in ophthalmology.

NTC sponsored a controlled study to test an innovative therapeutic solution called Blefastop in addressing blepharitis, an unmet medical and patient's need. The study was designed with aim to improve treatment efficacy, adherence and, consequently, eye health in patients suffering from blepharitis, enhancing patient's quality of life.

The study consisted in a randomized, controlled versus standard treatment with a closed sequential design of the efficacy, safety and patient-satisfaction of Blefastop for eyelid cleansing in patients affected by bilateral posterior blepharitis. Results evidenced a 70,6% patients in favor to Blefastop.

The final conclusions underline that Blefastop turned out to be more effective than standard treatment and no adverse events related to the treatment was recorded, indicating its absolute safety of use.

"It took a while to design, test and protect an innovative therapeutic solution in wipes like Blefastop. With its HY-TER technology, Blefastop wipes represent an effective adjuvant in the treatment for blepharitis, while being gentle on the eyelid. We worked in order to have a simple, effective therapeutic solution, gentle on the eyelid and well tolerated, simple to be used, and supported by clinical evidences. We leveraged also on technology to design Blefastop.

Blefastop in fact is available also in a combo package with an innovative device we developed, aimed at helping the patients to heat up to the ideal temperature their eyelids to facilitate the dissolving of the lipids that block the Meibomian glands, followed by the treatment with a Blefastop wipe. A sort of Heat, Clean and Treat approach. We offer Blefastop with a waterproof packaging for an improved clinical adherence. That also comes from the listening to ophthalmologists, since doctors tend to recommend that patients rinse their eyes daily, just like they brush their teeth, so keeping the Blefastop box on the sink near the toothbrush would make sense and possibly enhance daily use."

"We expect to have Blefastop registered in more than 60 countries and get it launched in most of them within end 2019", added Mr. Carbuicchio. "We are excited to offer Blefastop through our partners in many geographies to be able to contribute to help doctors to better treat their patients suffering from blepharitis. We trust Blefastop will turn to be one of our growth drivers in the coming years"